38 results on '"Ogasawara, Sadahisa"'
Search Results
2. Risk factors of unintentional piecemeal resection in endoscopic mucosal resection for colorectal polyps ≥ 10 mm
3. Outcomes for Underwater Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection of 21–30-mm Colorectal Polyps: A Feasible Study
4. Potential of circulating receptor-interacting protein kinase 3 levels as a marker of acute liver injury
5. Treatment strategy changes for inflammatory bowel diseases in biologic era: results from a multicenter cohort in Japan, Far East 1000
6. Cabozantinib for Advanced Hepatocellular Carcinoma in the Latest Real-World Practice: A Multicenter Retrospective Analysis
7. Estimation of the effect of atezolizumab plus bevacizumab on pulmonary arterial hypertension using computed tomography in HCC patients
8. Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice
9. Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma
10. Somatic mutations can induce a noninflamed tumour microenvironment via their original gene functions, despite deriving neoantigens
11. Phase II study comparing nasal pressure monitoring with capnography during invasive endoscopic procedures: a single-center, single-arm trial
12. The long-term effect of biologics in patients with ulcerative colitis emerging from a large Japanese cohort
13. The efficacy of contrast-enhanced computed tomography on the management of gastroesophageal varices in patients with hepatocellular carcinoma
14. “Salvage techniques” are the key to overcome difficult biliary cannulation in endoscopic retrograde cholangiopancreatography
15. Liver biopsy technique in the era of genomic cancer therapies: a single-center retrospective analysis
16. Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment
17. Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents
18. EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma
19. Diagnostic value of peroral cholangioscopy in addition to computed tomography for indeterminate biliary strictures
20. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma
21. Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma
22. Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study
23. Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan
24. Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection
25. Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment
26. Application of transcutaneous ultrasonography for the diagnosis of muscle mass loss in patients with liver cirrhosis
27. Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update
28. Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib
29. Liver function assessment according to the Albumin–Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma
30. Sorafenib treatment in Child–Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors
31. Incidental tumor necrosis caused by the interventional alteration of hepatic arterial flow in patients with advanced hepatocellular carcinoma
32. A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma
33. A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma
34. Is intra-patient sorafenib dose re-escalation safe and tolerable in patients with advanced hepatocellular carcinoma?
35. Coronal reformatted CT images contribute to the precise evaluation of the radiofrequency ablative margin for hepatocellular carcinoma
36. Clinical features and natural history of portal vein thrombosis after radiofrequency ablation for hepatocellular carcinoma in Japan
37. Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma
38. Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.